Europe Burns, US Measles Surges, and Science Turns on Long COVID

Today's health roundup spans a continent-wide heat emergency, a historic inflection point for measles control in the United States, and a trio of research papers that complicate daily decisions millions of people make — about supplements, sweeteners, and the drugs left over from COVID-19.

Wednesday, 16 July: WHO Tells Europe That Heat Deaths Are Not Inevitable — But Only If Countries Act Now

With nearly 10,000 excess deaths already recorded across five European countries this summer, the World Health Organization's European office issued updated Heat-Health Action Plan (HHAP) guidance on 16 July, pressing every member state to adopt formal written plans before the next extreme-temperature event. The guidance specifies eight non-negotiable components: a governance structure, an early-warning system, designated cool spaces for vulnerable residents, targeted communications, resilient health infrastructure, reduced-exposure measures, disease surveillance, and an evaluation framework. WHO Europe Director Dr. Hans Kluge stated plainly that "heat deaths are not inevitable" — but more than half of European countries still lack an approved HHAP. Heat-related mortality across the WHO European region has increased 30% over the past two decades, and a 2026 Lancet Countdown report warned that the window for decisive health action is narrowing. For Cyprus and the broader eastern Mediterranean — where July temperatures routinely exceed 38°C — the guidance carries immediate weight: WHO is asking national authorities to use the Hospital Safety Index to assess facility readiness, secure backup cooling infrastructure, and train staff to recognise and treat heat-related illness early.

Wednesday, 16 July: US Measles Passes 2,260 Cases — and the Country's Elimination Status Is Now at Risk

The US Centers for Disease Control and Prevention updated its national measles count to 2,260 confirmed cases in 34 active outbreaks as of 16 July — a figure that has nearly matched the country's full-year 2025 total with five months of high-transmission season still ahead. The proximate cause is well-documented: national childhood vaccination coverage has slipped from 95.2% in the 2019–2020 school year to 92.5% in 2024–2025, below the 95% community-immunity threshold that measles requires. Ninety-three percent of 2026 cases occurred in people who were either unvaccinated or whose vaccination status was unknown. Health authorities will formally reassess the country's elimination status — first granted in 2000 — in November; losing it would mark the first such reversal in 26 years and carries real epidemiological consequences: measles is among the most contagious pathogens known, and communities with sub-threshold vaccination coverage remain vulnerable to sustained chains of transmission.

Saturday, 18 July: A Common, Low-Cost Antidepressant Significantly Reduced Long COVID Fatigue in a Randomised Trial

The REVIVE-TOGETHER trial — a double-blind, placebo-controlled study enrolling 399 adults in Brazil who had experienced debilitating fatigue for at least 90 days after confirmed SARS-CoV-2 infection — has produced the most rigorous evidence yet for a pharmaceutical intervention against long COVID fatigue. Participants were randomly assigned to receive fluvoxamine (a widely available SSRI antidepressant), metformin (a common diabetes drug), or placebo for 60 days. After 30 days, those taking fluvoxamine were nearly 50% more likely than those on placebo to rate their fatigue at three or below on a seven-point scale; after 60 days, the benefit remained — fluvoxamine recipients were 36% more likely to reach that threshold. Metformin offered no meaningful benefit. The findings — published in the Annals of Internal Medicine by Reis et al. — matter beyond their statistical significance: fluvoxamine is already on the market at very low cost in most countries, meaning that if the benefit holds up across further trials and broader populations, a treatment could reach patients quickly and without prohibitive expense. The proposed mechanism — fluvoxamine's sigma-1 receptor agonism modulating neuroinflammation — remains under investigation, but the trial design was rigorous and the result clear.

Thursday, 17 July: Prospective Study of ~13,000 Adults Links Six Common Sweeteners to Faster Cognitive Ageing

A large prospective cohort study published in Neurology — the journal of the American Academy of Neurology — followed nearly 13,000 adults over approximately eight years, tracking verbal fluency, working memory, word recall, and processing speed, while measuring dietary intake of seven low- or no-calorie sweeteners: aspartame, saccharin, acesulfame-K, erythritol, xylitol, sorbitol, and tagatose. People in the highest consumption tier showed cognitive ageing roughly 1.6 years faster than those in the lowest tier. Six of the seven sweeteners were associated with measurable decline; tagatose was the exception. The effect was strongest in adults under 60 and in those with diabetes — populations already at elevated risk for cognitive impairment. Researchers were explicit about the study's limits: it is observational, cannot establish causation, and reverse causation and confounding remain plausible. Still, a study of this scale, duration, and journal stature warrants serious attention, and clinicians will likely begin fielding questions from patients who rely on these sweeteners daily, particularly in conversations about dementia prevention.

Thursday, 17 July: Creatine Fuels the Immune Sentinels That Train Cancer-Killing T Cells — in Mice

Researchers at UCLA published a study in iScience showing that creatine — the dietary supplement long associated with athletic performance — provides a critical energy boost to dendritic cells, the immune sentinels that detect tumour fragments and train killer T cells to attack. In mice with melanoma, supplementing creatine slowed tumour growth and increased the density of dendritic cells inside tumours; in human dendritic cells tested in laboratory dishes, creatine enhanced activation and improved the cells' capacity to prime T cell responses. The finding opens a mechanistically credible path toward combination strategies with existing immunotherapies: most approved checkpoint inhibitors work by releasing the brakes on killer T cells, but only 20–40% of cancer patients respond to them. Bolstering the upstream dendritic cells that activate those T cells could in theory expand that window. The work is preclinical — it has not been tested in cancer patients, and the relevant human dose is unknown — but the mechanistic clarity is notable, and the researchers say human trials are a logical next step.

The reporting above is journalistic in nature and does not constitute medical advice. Readers should consult a qualified clinician before making any change to their treatment, diet, or medication.